High-Grade Glioma - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 94 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

High-Grade Glioma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'High-Grade Glioma - Pipeline Review, H2 2014', provides an overview of the High-Grade Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for High-Grade Glioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the High-Grade Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the High-Grade Glioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
High-Grade Glioma Overview 8
Therapeutics Development 9
Pipeline Products for High-Grade Glioma - Overview 9
Pipeline Products for High-Grade Glioma - Comparative Analysis 10
High-Grade Glioma - Therapeutics under Development by Companies 11
High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes 12
High-Grade Glioma - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
High-Grade Glioma - Products under Development by Companies 15
High-Grade Glioma - Products under Investigation by Universities/Institutes 16
High-Grade Glioma - Companies Involved in Therapeutics Development 17
AngioChem Inc. 17
Bayer AG 18
Boehringer Ingelheim GmbH 19
Cavion LLC 20
GlaxoSmithKline plc 21
Millennium Pharmaceuticals, Inc. 22
Stemline Therapeutics, Inc. 23
Tocagen Inc. 24
Virttu Biologics Limited 25
High-Grade Glioma - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
alisertib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ANG-1005 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Cell Therapy for Gliomas - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
crenolanib besylate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Dendritic Cell Therapy for Oncology - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HSV-1716 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
mibefradil dihydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
nintedanib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SL-701 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
sorafenib tosylate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Stem Cell Therapy for Glioma - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
TBX-01 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Toca- RNAi - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Toca-Gamma - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
High-Grade Glioma - Recent Pipeline Updates 70
High-Grade Glioma - Dormant Projects 91
High-Grade Glioma - Discontinued Products 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94

List of Tables
Number of Products under Development for High-Grade Glioma, H2 2014 9
Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
High-Grade Glioma - Pipeline by AngioChem Inc., H2 2014 17
High-Grade Glioma - Pipeline by Bayer AG, H2 2014 18
High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 19
High-Grade Glioma - Pipeline by Cavion LLC, H2 2014 20
High-Grade Glioma - Pipeline by GlaxoSmithKline plc, H2 2014 21
High-Grade Glioma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 22
High-Grade Glioma - Pipeline by Stemline Therapeutics, Inc., H2 2014 23
High-Grade Glioma - Pipeline by Tocagen Inc., H2 2014 24
High-Grade Glioma - Pipeline by Virttu Biologics Limited, H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Assessment by Combination Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
High-Grade Glioma Therapeutics - Recent Pipeline Updates, H2 2014 70
High-Grade Glioma - Dormant Projects, H2 2014 91
High-Grade Glioma - Discontinued Products, H2 2014 92